Advanced Nanomedicines for Treating Refractory Inflammation-Related Diseases

IF 36.3 1区材料科学 Q1 Engineering

Nano-Micro Letters Pub Date : 2025-07-07 DOI:10.1007/s40820-025-01829-7

Xiuxiu Wang, Xinran Song, Wei Feng, Meiqi Chang, Jishun Yang, Yu Chen

引用次数: 0

Abstract

Highlights

An overview of inflammation related diseases has been provided.
The classification of nanomaterials commonly utilized in the treatment of various inflammatory diseases has been outlined.
The current state of nanomedical applications with desirable therapeutic efficacy in the treatment of inflammatory diseases has been sum marized.
The challenges and perspectives in the evolving field of nanomedicine for treating inflammatory diseases have been discussed and proposed in depth.

查看原文本刊更多论文

治疗难治性炎症相关疾病的先进纳米药物。

这篇综述探讨了炎症作为一种生理防御机制，可以抵抗感染因子、物理创伤、活性氧（ROS）和代谢应激，这些在失调的条件下可能发展成慢性疾病。纳米医学将纳米技术与医学相结合，抑制炎症信号通路和过度表达的促炎细胞因子，如ROS，以解决炎症相关病理。系统分析了纳米材料设计和合成策略的最新进展，并对毒性机制、影响因素和评估方法进行了平行讨论，这些对临床转化至关重要。功能性纳米材料的应用重点是在难治性炎症条件下，包括伤口愈合、胃肠道疾病、免疫、神经或循环系统疾病，以及靶向递送策略。在纳米药物的发展，如生物相容性优化，精确的生物分布控制和标准化的毒性评估持续挑战，严格评估。通过将材料创新与治疗效果联系起来，本综述建立了一个推进纳米医学的框架，以改善治疗结果，同时解决转化障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nano-Micro Letters NANOSCIENCE & NANOTECHNOLOGY-MATERIALS SCIENCE, MULTIDISCIPLINARY

CiteScore

32.60

自引率

4.90%

发文量

981

审稿时长

1.1 months

期刊介绍： Nano-Micro Letters is a peer-reviewed, international, interdisciplinary, and open-access journal published under the SpringerOpen brand. Nano-Micro Letters focuses on the science, experiments, engineering, technologies, and applications of nano- or microscale structures and systems in various fields such as physics, chemistry, biology, material science, and pharmacy.It also explores the expanding interfaces between these fields. Nano-Micro Letters particularly emphasizes the bottom-up approach in the length scale from nano to micro. This approach is crucial for achieving industrial applications in nanotechnology, as it involves the assembly, modification, and control of nanostructures on a microscale.